Combination of Anti-HER3 Antibody MM-121/SAR256212 and Cetuximab Inhibits Tumor Growth in Preclinical Models of Head and Neck Squamous Cell Carcinoma (HNSCC)

The EGFR monoclonal antibody cetuximab is the only approved targeted agent for treating head and neck squamous cell carcinoma (HNSCC). Yet resistance to cetuximab has hindered its activity in this disease. Intrinsic or compensatory HER3 signaling may contribute to cetuximab resistance. To investigat...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Jiang, Ning, Wang, Dongsheng, Hu, Zhongliang, Shin, Hyung Ju C., Qian, Guoqing, Rahman, Mohammad Aminur, Zhang, Hongzheng, Amin, A.R.M. Ruhul, Nannapaneni, Sreenivas, Wang, Xiaojing, Chen, Zhengjia, Garcia, Gabriela, MacBeath, Gavin, Shin, Dong M., Khuri, Fadlo R., Ma, Jun, Chen, Zhuo G., Saba, Nabil F.
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4090261/
https://ncbi.nlm.nih.gov/pubmed/24748655
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-13-1093
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados